Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siEGFR-SWCNT
- Development stage
- Preclinical
- Lead developer
- Ensysce Biosciences
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**siEGFR-SWCNT** is an investigational, intravenously administered single-walled carbon nanotube delivery formulation carrying a small interfering RNA directed against **epidermal growth factor receptor**. Developed by Ensysce, the formulation was evaluated preclinically in EGFR-overexpressing A431 human epidermoid carcinoma xenografts. The siRNA component is intended to reduce EGFR expression in tumor tissue, while PEG-lipid-formulated single-walled carbon nanotubes improve systemic circulation and tumor accumulation. In the reported mouse xenograft study, an optimized formulation produced EGFR knockdown of up to 90% and delayed tumor growth by 16 to 20 days relative to free-siRNA control treatment.
- Other names
- SWCNT/siEGFR
02
Targets
Beyond the preview
Go deeper on siEGFR-SWCNT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siEGFR-SWCNT.